Literature DB >> 15834042

Cognitive patterns and progression in multiple sclerosis: construction and validation of percentile curves.

A Achiron1, M Polliack, S M Rao, Y Barak, M Lavie, N Appelboim, Y Harel.   

Abstract

BACKGROUND AND OBJECTIVES: Rate and pattern of progression of cognitive decline in multiple sclerosis (MS) has not been clearly identified. The present study aimed to identify correlations between cognitive tests and disease duration, construct longitudinal cognitive curves, and assess pattern of change over time.
METHODS: The Neuropsychological Screening Battery for Multiple Sclerosis was administered in 150 consecutive MS patients, and tests that correlated with disease duration were identified. Percentile curves were constructed and the pattern of cognitive decline over time explored. The cognitive curves were validated in an additional group of 83 patients with MS.
RESULTS: Three of four measures of the spatial recall test (SPART 7/24), and the paced auditory serial addition task for two seconds (PASAT 2'), correlated with disease duration. These tests were used to construct cross-sectional curves identifying the pattern of cognitive decline over time in the MS population. On the basis of this cross-sectional analysis, the earliest cognitive decline occurred in the SPART 7/24 trials 1-5 between one and three years from onset, followed by decline in the SPART delayed recall between three and seven years, and then by decline in the PASAT 2' after seven years from onset.
CONCLUSIONS: Verbal fluency and verbal memory appear to be affected earliest in MS. The pattern of cognitive decline is further characterised by a decrease in visuospatial learning, followed by delayed recall, and then by attention and information processing speed. Cognitive percentile curves can be used to evaluate the pattern of progression and identify patients at increased risk.

Entities:  

Mesh:

Year:  2005        PMID: 15834042      PMCID: PMC1739629          DOI: 10.1136/jnnp.2004.045518

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  22 in total

1.  Subcutaneous Interferon Beta-1a Has a Positive Effect on Cognitive Performance in Mildly Disabled Patients with Relapsing-Remitting Multiple Sclerosis: 2-Year Results from the COGIMUS Study.

Authors:  Francesco Patti; Maria Pia Amato; Stefano Bastianello; Luisa Caniatti; Elisabetta Di Monte; Fausto Lijoi; Benedetta Goretti; Silvia Messina; Orietta Picconi; Maria Rosalia Tola; Maria Trojano
Journal:  Ther Adv Neurol Disord       Date:  2009-03       Impact factor: 6.570

2.  Experimental Autoimmune Encephalomyelitis Ameliorated by Passive Transfer of Polymerase 1-Silenced MOG35-55 Lymphatic Node Cells: Verification of a Novel Therapeutic Approach in Multiple Sclerosis.

Authors:  R Zilkha-Falb; M Gurevich; A Achiron
Journal:  Neuromolecular Med       Date:  2017-07-28       Impact factor: 3.843

Review 3.  Meta-analysis of cognitive performance in fibromyalgia.

Authors:  Tyler Bell; Zina Trost; Melissa T Buelow; Olivio Clay; Jarred Younger; David Moore; Michael Crowe
Journal:  J Clin Exp Neuropsychol       Date:  2018-02-01       Impact factor: 2.475

4.  Cognitive dysfunction in patients with multiple sclerosis treated with first-line disease-modifying therapy: a multi-center, controlled study using the BICAMS battery.

Authors:  Bilge Piri Cinar; Görkem Kösehasanoğulları; Pinar Yigit; Serkan Ozakbas
Journal:  Neurol Sci       Date:  2016-11-24       Impact factor: 3.307

Review 5.  Causes, effects and connectivity changes in MS-related cognitive decline.

Authors:  Carolina de Medeiros Rimkus; Martijn D Steenwijk; Frederik Barkhof
Journal:  Dement Neuropsychol       Date:  2016 Jan-Mar

6.  Processing speed versus working memory: contributions to an information-processing task in multiple sclerosis.

Authors:  Helen M Genova; Jeannie Lengenfelder; Nancy D Chiaravalloti; Nancy B Moore; John DeLuca
Journal:  Appl Neuropsychol Adult       Date:  2012       Impact factor: 2.248

Review 7.  Ocular motor signatures of cognitive dysfunction in multiple sclerosis.

Authors:  Joanne Fielding; Meaghan Clough; Shin Beh; Lynette Millist; Derek Sears; Ashley N Frohman; Nathaniel Lizak; Jayne Lim; Scott Kolbe; Robert L Rennaker; Teresa C Frohman; Owen B White; Elliot M Frohman
Journal:  Nat Rev Neurol       Date:  2015-09-15       Impact factor: 42.937

8.  The role of disability and depression in cognitive functioning within 2 years after multiple sclerosis diagnosis.

Authors:  T A M Siepman; A C J W Janssens; I de Koning; C H Polman; J B Boringa; R Q Hintzen
Journal:  J Neurol       Date:  2008-05-20       Impact factor: 4.849

Review 9.  Relationship between brain volume loss and cognitive outcomes among patients with multiple sclerosis: a systematic literature review.

Authors:  Timothy Vollmer; Lynn Huynh; Caroline Kelley; Philip Galebach; James Signorovitch; Allitia DiBernardo; Rahul Sasane
Journal:  Neurol Sci       Date:  2015-11-04       Impact factor: 3.307

10.  Subcutaneous interferon β-1a may protect against cognitive impairment in patients with relapsing-remitting multiple sclerosis: 5-year follow-up of the COGIMUS study.

Authors:  Francesco Patti; Vincenzo Brescia Morra; Maria Pia Amato; Maria Trojano; Stefano Bastianello; Maria Rosalia Tola; Salvatore Cottone; Andrea Plant; Orietta Picconi
Journal:  PLoS One       Date:  2013-08-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.